- Home
- PHVS
PHVS
Pharvaris N.V.
as of 06-04-2026 4:00pm EST
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
| Founded: | 2015 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $41.82 | AVG Volume (30 days): | 319.5K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $16.00 - $33.33 | Next Earning Date: | 05-12-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered PHVS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Pharvaris N.V. (PHVS)
Principal Accounting Officer
Avg Cost/Share
$30.74
Shares
5,501
Total Value
$169,084.24
Owned After
48,945
SEC Form 4
Director
Avg Cost/Share
$30.29
Shares
9,667
Total Value
$292,853.06
Owned After
5,500
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$30.60
Shares
1,829
Total Value
$55,971.24
Owned After
48,945
SEC Form 4
CFO / CLO
Avg Cost/Share
$30.31
Shares
10,000
Total Value
$303,076.00
Owned After
120,300
SEC Form 4
Director
Avg Cost/Share
$29.32
Shares
10,000
Total Value
$293,166.00
Owned After
15,167
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$29.22
Shares
2,292
Total Value
$66,976.82
Owned After
137,500
SEC Form 4
Chief Early Development
Avg Cost/Share
$30.03
Shares
200
Total Value
$6,006.00
Owned After
56,450
Avg Cost/Share
$30.03
Shares
100
Total Value
$3,003.00
Owned After
388,067
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Nijdam Anna | PHVS | Principal Accounting Officer | May 22, 2026 | Sell | $30.74 | 5,501 | $169,084.24 | 48,945 | |
| Monges Viviane | PHVS | Director | May 21, 2026 | Sell | $30.29 | 9,667 | $292,853.06 | 5,500 | |
| Nijdam Anna | PHVS | Principal Accounting Officer | May 21, 2026 | Sell | $30.60 | 1,829 | $55,971.24 | 48,945 | |
| Nassif David W. | PHVS | CFO / CLO | May 21, 2026 | Sell | $30.31 | 10,000 | $303,076.00 | 120,300 | |
| Bjork Elisabeth | PHVS | Director | May 20, 2026 | Sell | $29.32 | 10,000 | $293,166.00 | 15,167 | |
| Modig Berndt | PHVS | Chief Executive Officer | May 18, 2026 | Sell | $29.22 | 2,292 | $66,976.82 | 137,500 | |
| Lu Peng | PHVS | Chief Medical Officer | May 1, 2026 | Sell | $30.58 | 14,166 | $427,418.57 | 66,083 | |
| Lu Peng | PHVS | Chief Medical Officer | Apr 23, 2026 | Sell | $30.03 | 100 | $3,003.00 | 66,083 | |
| Lesage Anne | PHVS | Chief Early Development | Apr 23, 2026 | Sell | $30.03 | 200 | $6,006.00 | 56,450 | |
| Schikan Johannes Gerardus Christiaan Petrus | PHVS | Director | Apr 23, 2026 | Sell | $30.03 | 100 | $3,003.00 | 388,067 |
Compare PHVS vs Leading Stocks
See how PHVS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PHVS Pharvaris N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.